Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1576 - 1600 of 1913 in total
Nalorphine is a mixed opioid agonist–antagonist. It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics. It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence.
Experimental
Vet approved
Matched Iupac: … (1S,5R,13R,14S,17R)-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca …
Experimental
Matched Iupac: … {1,10}.0^{2,8}]heptadec-13-ene-9-carboxylic acid ... ,5S,8S,9S,10R,11R,12S)-5,12-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.1^{5,8}.0^ …
Cinpanemab is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).
Investigational
Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.
Investigational
Doxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7. As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. In contrast with other xanthine derivatives, doxofylline does...
Experimental
Experimental
Matched Iupac: … 1-(2-{1-ferra-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2-yl}ethyl)-2,5-dihydro-1H-pyrrole …
A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the gamma-aminobutyric acid-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]
Experimental
Matched Iupac: … -trioxapentacyclo[6.4.1.1^{9,12}.0^{3,5}.0^{5,13}]tetradecane-6,11-dione ... 5S,8S,13R,14S)-1-hydroxy-14-(2-hydroxypropan-2-yl)-13-methyl-4,7,10-trioxapentacyclo[6.4.1.1^{9,12}.0^ ... {3,5}.0^{5,13}]tetradecane-6,11-dione; (1R,5S,8S,13R,14R)-1-hydroxy-13-methyl-14-(prop-1-en-2-yl)-4,7,10 …
Experimental
Illicit
Matched Iupac: … .0^{7,18}]octadeca-7(18),8,10,15-tetraen-4-ium bromide ... (1S,5R,13R,14S,17R)-14-hydroxy-10-methoxy-4,4-dimethyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17} …
Experimental
Matched Iupac: … 4,9}.0^{15,20}]icosa-1(13),3(11),4(9),5,7,15(20),16,18-octaene-1,3-bis(ylium) ... 7,17-bis(diaminomethyl)-12-oxo-1lambda5,3lambda5,10,14-tetraaza-2-zincapentacyclo[11.7.0.0^{3,11}.0^{ …
Experimental
Illicit
Matched Iupac: … (1S,4S,5R,13R,14S,17R)-14-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0
Experimental
Matched Iupac: … {4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate ... diethylamino)ethyl]-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^ …
Investigational
Veligrotug is under investigation in clinical trial NCT00791544 (Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma).
Investigational
Experimental
Illicit
Matched Iupac: … (1S,5R,13R,14S,17S)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10 …
Illicit
Matched Iupac: … (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6-oxa-5,7-diazapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18 …
Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors. Merck has...
Investigational
Matched Iupac: … (7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(15),8,10,12,16,18-hexaene …
Dihydrexidine has been used in trials studying the treatment of SPD, Cocaine-Related Disorders, and Schizotypal Personality Disorder.
Investigational
Matched Iupac: … (1R,10S)-9-azatetracyclo[8.8.0.0^{2,7}.0^{13,18}]octadeca-2,4,6,13,15,17-hexaene-15,16-diol …
Rebeccamycin is a weak topoisomerase I inhibitor isolated from Nocardia sp.
Experimental
Matched Iupac: … {4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4(9),5,7,11(15),17(22),18,20-nonaene-12,14-dione ... ,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^ …
Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
Investigational
Selitrectinib is under investigation in clinical trial NCT03215511 (Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers).
Investigational
Matched Iupac: … (6R,15R)-9-fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.0^{2,6}.0^{7,12}.0^{21,25}]pentacosa …
18-methoxycoronaridine is under investigation in clinical trial NCT03084952 (Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients).
Investigational
Matched Iupac: … methyl (1S,15R,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.0^{2,10}.0^{4,9}.0^{13,18}]nonadeca …
Investigational
Matched Iupac: … }.0^{18,22}]docosa-1(22),4(12),6,8,10,18,20-heptaene ... (15S)-21-fluoro-10-(2-methylpyridin-3-yl)-13,17-dioxa-3,5,7,8-tetraazapentacyclo[13.6.1.0^{4,12}.0^{5,9 …
Experimental
Matched Iupac: … }.0^{7,18}]octadeca-7(18),8,10,15-tetraen-10-yl pyridine-3-carboxylate ... (1S,5R,13R,14S,17R)-4-methyl-14-(pyridine-3-carbonyloxy)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17 …
Experimental
Matched Iupac: … {27,31}.0^{22,33}]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24(32),25,27(31),35-dodecaene ... 9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2^{3,6}.1^{8,12}.1^{14,18}.0^ …
Fluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography).
Investigational
Matched Iupac: … {4,8}.0^{13,18}]icos-17-en-16-one ... 6R,8S,9S,12S,13R)-8-[2-(¹⁸F)fluoroacetyl]-6-(furan-2-yl)-9-methyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^ …
Displaying drugs 1576 - 1600 of 1913 in total